Contact
searchSearch
HMP Global

Dermatology Topic Center

News
New Treatment for Vitiligo Offers Long-Term Cost Savings and High Repigmentation Success
04/14/2025
Lisa Kuhns, PhD, MD
A novel treatment for stable vitiligo combining autologous skin cell suspension (ASCS) with phototherapy has demonstrated both clinical success and long-term cost savings when compared to phototherapy alone, according to study results...
A novel treatment for stable vitiligo combining autologous skin cell suspension (ASCS) with phototherapy has demonstrated both clinical success and long-term cost savings when compared to phototherapy alone, according to study results...
A novel treatment for stable...
04/14/2025
First Report Managed Care
News
Patients With Vitiligo Face Elevated Risk of Cardiovascular Disease, Study Finds
03/14/2025
Grace Taylor, MS, MA
Individuals with vitiligo have an increased risk of major cardiovascular events, including stroke and venous thromboembolism, according to researchers.
Individuals with vitiligo have an increased risk of major cardiovascular events, including stroke and venous thromboembolism, according to researchers.
Individuals with vitiligo have...
03/14/2025
First Report Managed Care
News
Artificial Intelligence Enhances Facial Vitiligo Assessment With High Accuracy
02/18/2025
Lisa Kuhns, PhD, MD
A new artificial intelligence (AI) algorithm has demonstrated high accuracy in assessing facial vitiligo, offering a faster and more objective method for evaluating disease severity and treatment response, according to a study published in...
A new artificial intelligence (AI) algorithm has demonstrated high accuracy in assessing facial vitiligo, offering a faster and more objective method for evaluating disease severity and treatment response, according to a study published in...
A new artificial intelligence...
02/18/2025
First Report Managed Care
News
The Real-World Impact of Ruxolitinib Cream for Patients With Atopic Dermatitis
02/10/2025
Hannah Musick
The use of ruxolitinib cream for atopic dermatitis shows promise in decreasing the need for other treatments, with reductions in oral corticosteroid use observed in some patients.
The use of ruxolitinib cream for atopic dermatitis shows promise in decreasing the need for other treatments, with reductions in oral corticosteroid use observed in some patients.
The use of ruxolitinib cream for...
02/10/2025
First Report Managed Care
News
Study Highlights the Substantial Economic and Health Care Burden of Vitiligo
01/13/2025
Lisa Kuhns, PhD, MD
Patients with vitiligo in the US face significantly higher health care costs and resource utilization compared with the general population, according to a study published in the Journal of Investigative Dermatology.
Patients with vitiligo in the US face significantly higher health care costs and resource utilization compared with the general population, according to a study published in the Journal of Investigative Dermatology.
Patients with vitiligo in the US...
01/13/2025
First Report Managed Care
Conference Coverage
Multi-Year Educational Initiative Aims to Expand Understanding of Atopic Dermatitis for Managed Care Professionals
04/11/2024
Hannah Musick
An educational initiative aiming to improve access to high-quality care for individuals with atopic dermatitis by expanding managed care professionals' understanding of this condition will be presented at AMCP 2024.
An educational initiative aiming to improve access to high-quality care for individuals with atopic dermatitis by expanding managed care professionals' understanding of this condition will be presented at AMCP 2024.
An educational initiative aiming...
04/11/2024
First Report Managed Care
News
Comparing the Cost-Effectiveness of Phototherapy and Biologics for Psoriasis and Atopic Dermatitis Treatment
12/21/2023
Hannah Musick
"This study is necessary to allow physicians, patients, and health systems to make informed decisions regarding cost-efficacy for a variety of treatment options," said researchers.
"This study is necessary to allow physicians, patients, and health systems to make informed decisions regarding cost-efficacy for a variety of treatment options," said researchers.
"This study is necessary to...
12/21/2023
First Report Managed Care
Commentary
Study Explores the Psychological Effect of Living With Vitiligo and its Impact on Patient Quality of Life
12/20/2023
Yvette C. Terrie, BS Pharm, RPh
Clinicians should consider both the physical and psychological aspects of living with vitiligo and implement measures to identify and efficaciously address them, which can improve patient adherence, clinical outcomes, patient well-being, and...
Clinicians should consider both the physical and psychological aspects of living with vitiligo and implement measures to identify and efficaciously address them, which can improve patient adherence, clinical outcomes, patient well-being, and...
Clinicians should consider both...
12/20/2023
First Report Managed Care
Commentary
The Role of JAK Inhibitors in the Treatment of Autoimmune and Autoinflammatory Diseases
12/14/2023
Yvette C. Terrie, BS Pharm, RPh
While the majority of Janus kinase inhibitors (JAKs) are available in oral formulations, in July 2022, the FDA approved ruxolitinib cream 1.5% as the only topical formulation of a selective JAK (JAK1/JAK2) inhibitor approved in the US,...
While the majority of Janus kinase inhibitors (JAKs) are available in oral formulations, in July 2022, the FDA approved ruxolitinib cream 1.5% as the only topical formulation of a selective JAK (JAK1/JAK2) inhibitor approved in the US,...
While the majority of Janus...
12/14/2023
First Report Managed Care
Commentary
Real-World Study Highlights a Need to Improve Treatment Initiation in Patients With Vitiligo
11/20/2023
Yvette C. Terrie, BS Pharm, RPh
Since nonsegmental vitiligo is the most common type of vitiligo, the availability of the targeted therapy, Opzelura (topical ruxolitinib) cream, has the potential to help many patients living with vitiligo when appropriate. Improving access...
Since nonsegmental vitiligo is the most common type of vitiligo, the availability of the targeted therapy, Opzelura (topical ruxolitinib) cream, has the potential to help many patients living with vitiligo when appropriate. Improving access...
Since nonsegmental vitiligo is...
11/20/2023
First Report Managed Care

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use